For digital health companies, the U.S. market is critical for unlocking the full commercial value of their products and/or gaining the confidence of early/mid-stage investors to fund business growth. In this paper, we outline our approach to developing U.S. go-to-market (GTM) strategies for ex-U.S. companies. We also offer some additional commentary on the top keys to success.
